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Abstract. Two elderly patients with Parkinson's disease 
were treated with nicotine gum and patch. Reliable 
changes in symptomatology were noted, using a single- 
subject, placebo-control reversal design. Improvement 
was associated with active nicotine dosing and involved 
diminished tremor and disorganized thinking in one pa- 
tient and diminished bradykinesia and increased energy 
in the other. 
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A negative relationship between Parkinson's disease 
(PD) and tobacco smoking has frequently been noted 
(Baron 1986). Of particular relevance to the neuropa- 
thology of PD is that through its effects on cholinergic 
pathways, nicotine - the psychoactive constituent in to- 
bacco - modulates dopamine (DA) activity by exerting 
an excitatory action at the level of DA nerve cells in the 
substantia nigra (Lichtensteiger et al. 1982). Several in- 
vestigators have noted that repeated administration of 
nicotine leads to potentiation of mesolimbic DA secre- 
tion as well as to enhanced locomotor responsivity in an- 
imals (Kita et al. 1992), and chronic nicotine dosing has 
been shown to protect against degeneration of central 
DA neurons induced by mechanical lesions (Fuxe et al. 
1991). Despite encouraging results in a 1926 case study 
by Moll (1926), in which post-encephalitic parkinsonism 
patients were treated with nicotine, we are not aware of 
other reports on the use of nicotine in the management 
of PD. Below, we describe the clinical response to nico- 
tine in two PD patients. 
Case 1 
The first patient, a never-smoker, was a 69-year-old 
woman exhibiting predominantly dystonic PD symp- 
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toms. During the 15-month therapeutic period, the pa- 
tient received Disipal (orphenadine, 50 mg 5 times/day). 
(L-Dopa had been administered shortly after the initial 
diagnosis but with little effect, suggesting atypical PD.) 
The patient was treated in an open trial with nicotine 
polacrilex (Nicorette gum) for 7 months. As she had 
evinced considerable benefit from nicotine starting from 
the second month of nicotine use, she was asked to serve 
as a research subject. To elucidate more precisely the 
role of nicotine, a double-blind (patient, rater, and dis- 
penser blind to conditions), placebo-controlled dose-re- 
versal study was initiated. 
Phase A. Eight pieces of 4 mg polacrilex gum/day (each 
piece yielded about 1.5 mg nicotine) for 5 days. 
Phase B. Nicotine 15 mg per day via 16-h transdermal 
patch over the next 7 days. 
Phase C. Placebo patch treatment (nicotine washout) for 
7 days. 
Phase D. Nicotine 15 mg patch treatment for a final 7 
days. 
The patient and an observer (patient's son) rated 
tremor, rigidity, sleep, and disorganized thinking over 
the 26-day trial; the ratings shown in Fig. 1 are means of 
assessments of symptoms. 
Clinical benefits included decreased tremor, less mus- 
cular rigidity, and a reduction in disorganized thinking; 
sleep was much improved due to a reduction in dystonic 
movements. As can be seen, introduction of placebo was 
associated with deterioration on all symptom measures 
(Student's-test; P<0.01), and return to active patch was 
associated with restoration of benefits (Student's-test; 
P>0.01). After completion of the experimental manipu- 
lations, the patient was maintained on a regimen of 15 
mg patch plus four pieces of 4 mg gum per day, resulting 
in a plasma level of cotinine (a nicotine metabolite with 
a half-life of app. 20 h) of 525 ng/ml, a level comparable 
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to that of a heavy cigarette smoker. Fifteen months after 
the experimental manipulations (23 months from the be- 
ginning of nicotine therapy), the patient and her son both 
indicate that the improvements have been sustained. 
Case  2 
The second patient, a former smoker, was a 64-year-old 
man exhibiting characteristic features of PD, including 
muscular rigidity, masked facies, blurred speech, and il- 
legible handwriting; while no resting tremor was evident 
at the time he was first seen, motor activity was slowed 
(bradykinesia) and rocking movements were evident 
several times a minute when the patient was sitting (dys- 
tonia was attributed to PD therapy). During the 8-month 
treatment period, the patient took Sinemet (car- 
bidopa[levodopa] 25/100 t.i.d.) and Eldepryl (MAO-B 
inhibitor[selegiline] 5 mg b.i.d.). 
At the time of the first visit, the patient's self-rated 
level of global function (pre-morbid level defined as 
100%) had declined to 20%, down precipitously from a 
high of nearly 100% when he first started taking Elde- 
pryl (5 years before) and Sinemet (6 years before). The 
patient reported that in order to avoid bradykinesia later 
in the day, he now required a nap of 4-5 h each after- 
noon (added to his usual 5-6 h of regular sleep). 
Nicotine treatment was initiated using t6-h nicotine 
patches, and dosing was supplemented by the addition of 
nicotine polacrilex a month later. With the exception of a 
transient problem with more frequent awakenings at 
night (which was managed by taking off one of the 
patches a few hours before bedtime), there were no nota- 
ble adverse events. To evaluate the therapeutic effects of 
nicotine, a double-blind (patient and raters blind to the 
conditions), placebo-controlled reversal design was 
used: 
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Fig. 2. Level of function, depressive mood, and cotinine level af- 
ter exposure to different nicotine dosages 
Condition A. No nicotine (baseline prior to nicotine dos- 
ing). 
Condition B. Maximum of 20 mg patch plus six pieces of 
4rag gum (distributed throughout the day) over 11 
weeks. 
Condition C. 20 mg patch plus up to 11 pieces of 4 mg 
gum (distributed throughout the day) over 4 weeks. 
Condition D. Placebo patch and placebo gum (nicotine 
washout) over 2 weeks. 
Condition E. Maximum of 35 mg patch plus up to four 
pieces of 4 mg gum (used only as needed) over t0 weeks. 
Compared with condition A (no nicotine) by condi- 
tion C (exposure to the higher nicotine dose), the patient 
reported more efficient sleep (feeling well rested in the 
morning), more energy (his afternoon nap went down to 
1-2 h and was often skipped), being able to carry out 
various tasks with renewed satisfaction, restoration of 
the ability to drive an automobile, and greatly improved 
mood and outlook; as corroborated both by the referring 
neurologist (who conducted independent examinations 
toward the end of each condition) and the patient's wife, 
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speech was clearer, handwriting was improved, facial 
expression of emotion was restored, and dystonic move- 
ments were nearly absent. Return to nicotine dosing in 
condition E (second exposure to high nicotine), restored 
function lost in condition D (nicotine wash out), through 
it took nearly 2 months to get back fully to the levels ob- 
served in condition C. 
As can be seen in Fig. 2, the patient's self-rating of 
overall function was directly related to cotinine levels 
which, in turn, were proportional to the nicotine dosage 
administered. Scores on the Geriatric Depression Scale 
(range 0-24; cutoff-score for depression, > 12) suggest 
that improvement shown in the two high nicotine-dose 
conditions involved changes in both mood and conduct 
of daily activities. The therapeutic response to nicotine 
treatment in the second patient, a former smoker, was 
entirely consistent with that observed in the first patient, 
a never-smoker. 
Comment 
We hope these observations will stimulate others to in- 
vestigate the use of  nicotine in the management of  ne- 
urodegenerative disorders. In his report on the treatment 
of PD, Moll stated that "treatment by nicotine failed to 
give any permanent cures, although the immediate re- 
sults were indisputable", and concluded that "treatment 
should therefore be repeated at frequent intervals". In 
Moll's study, nicotine was administered by hypodermic 
injection; today, nicotine can be administered with much 
greater convenience and safety by patch and polacrilex 
gum. 
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